Levofloxacin

Levofloxacin
Systematic (IUPAC) name
(S)-7-fluoro-6-(4-methylpiperazin-1-yl) -10-oxo-4-thia-1-azatricyclo[7.3.1.05,13] trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Identifiers
CAS number 100986-85-4
ATC code J01MA12 S01AX19
PubChem CID 149096
DrugBank APRD00477
ChemSpider 131410
Chemical data
Formula C18H20FN3O4 
Mol. mass 361.368 g/mol
SMILES eMolecules & PubChem
Synonyms (S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl) -7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij] quinoline-6-carboxylic acid
Pharmacokinetic data
Bioavailability 99%
Protein binding 24 to 38%
Metabolism Renal
Half-life 6 to 8 hours
Excretion Urinary
Therapeutic considerations
Pregnancy cat. C (United States)
Legal status Prescription Only
Routes Oral, IV, ophthalmic
 YesY(what is this?)  (verify)

Levofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class[1][2] and is used to treat severe or life-threatening bacterial infections or bacterial infections that have failed to respond to other antibiotic classes.[3][4] It is sold under various brand names, such as Levaquin and Tavanic, the most common. In form of ophthalmic solutions it is known as Oftaquix, Quixin and Iquix.

Levofloxacin is a chiral fluorinated carboxyquinolone. Investigation of ofloxacin, an older drug that is the racemic mixture, found that the l form [the (–)-(S) enantiomer] is more active. This specific component is levofloxacin.[5][6]

Levofloxacin interacts with a number of other drugs, as well as a number of herbal and natural supplements. Such interactions increase the risk of cardiotoxicity and arrhythmias, anticoagulation, the formation of non-absorbable complexes, as well as increasing the risk of toxicity.[7]

Levofloxacin is associated with a number of serious and life-threatening adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Such reactions may manifest long after therapy had been completed and in severe cases may result in life-long disabilities. Hepatoxicity has also been reported with the use of levofloxacin.[8][9]

Contents

History

Levofloxacin is a fluoroquinolone antibiotic, marketed by sanofi aventis under the tradename "TAVANIC".[10] Levaquin is also marketed worldwide for oral and IV use, as well as used in ophthalmic solutions. Daiichi Sankyo had granted an exclusive license to Sanofi-Aventis to make, use and sell pharmaceutical preparations containing levofloxacin in the UK and Mexico under the trade name TAVANIC.[11] Other manufacturers include Novell Pharmaceutical Laboratories (Levores).

Levaquin has proven to be a blockbuster drug for Johnson and Johnson / Ortho McNeil, generating billions of dollars in additional revenue. In 2007 alone, Levaquin accounted for 6.5% of Johnson and Johnson's total revenue, generating $1.6 billion, an 8% increase over the previous year.[12] Ranking 37th within the top 200 prescribed drugs in the United States for 2007, and ranked 19th in world sales in 2007, total sales for Levaquin were in excess of 1.6 billion dollars.[13] Levaquin was the most prescribed fluoroquinolone drug in the world for 2007.[14]

Levofloxacin was first patented in 1987 (Levofloxacin European patent – Daiichi Pharmaceutical Co., Ltd.) and was approved by the United States Food and Drug Administration on December 20, 1996[15] for use in the United States to treat severe and life-threatening bacterial infections. Within a significant number of medical publications and books levofloxacin is described as a second generation fluoroquinolone.[16][17][18] Where as within a number of medical web sites it has been described as a third-generation fluoroquinolone.[19][20]

Levofloxacin is considered to be same as Ofloxacin by the U.S. Food and Drug Administration (FDA), with the exception of the potency shown in vitro against mycobacteria. In vitro, it is, in general, twice as potent as ofloxacin, whereas d-ofloxacin is less active against mycobacteria.[21][22]

The current United States patent is held by Ortho-McNeil-Janssen.[13] Ranked 19th in world sales in 2007, sales for Levaquin exceeded $1.4 billion.[13] Levaquin was the most prescribed fluoroquinolone drug in the world for 2007.[23]

Levaquin sample boxes showed a line over the letter "e", indicating pronunciation with a long "e" sound, although Merriam-Webster indicates a soft "e" pronunciation. Levofloxacin would typically be pronounced with the long e from the Latin prefix "levo-" (meaning left).

Levofloxacin is marketed worldwide under a significant number of different brand names, making post-marketing surveillance difficult.[24][25]

In addition, generic versions of levofloxacin had been available since 2004 and marketed as a generic drug under a variety of different brand names. However, Daiichi Sankyo-Johnson and Johnson-Ortho McNeil filed numerous patent lawsuits to prevent such generic equivalents from being marketed, claiming that their patent did not expire until June 23, 2009.[26] see Generic equivalents

Licensed uses

The licensed uses for Oral and I.V. levofloxacin in the United States are as follows:

In the adult population Oral and I.V. levofloxacin is limited to the treatment of proven serious and life-threatening bacterial infections such as:

Within the pediatric population Oral and I.V. levofloxacin is limited to:

Note: Levofloxacin has shown moderate activity against anaerobes, and is about twice as potent as ofloxacin against mycobacterium tuberculosis and other mycobacteria, including mycobacterium avium complex.[37]

Oral and I.V. Levaquin are not licensed by the FDA for use in children other than the exception (inhalational anthrax),[38] due to the risk of reversible or irreversible[39] injury to the musculoskeletal system.[40] Although claimed to be effective, levofloxacin is not to be considered a first line agent for inhalational anthrax in the pediatric population due to severe adverse reactions involving the musculoskeletal system and other serious adverse reactions, including fatalities.[39][40][41][42][43][44][45]

The CDC revoked its recommendation regarding the use of fluoroquinolones (ciprofloxacin) as a first line agent in treating anthrax (in part) due to the risk of adverse reactions documented within the Antimicrobial Postexposure Prophylaxis for Anthrax study (aka Cipro 60-day study).[46] However, the fluoroquinolones are licensed to treat lower respiratory infections in children with cystic fibrosis in the UK.

Note: levofloxacin may be licensed for other uses, or restricted, by the various regulatory agencies worldwide.

Availability

Levofloxacin is available by prescription in tablet form (oral multiple strengths), injection (multiple strengths), solution (oral 250 mg/10ml), as well as used in prescription eye and ear drops.[5]

Contraindications

As noted above, under licensed use, levofloxacin is now considered to be contraindicated for the treatment of certain sexually transmitted diseases by some experts due to bacterial resistance.[47]

There is one contraindication now found within the 2008 package insert for Levaquin, namely that Levaquin is to be avoided in patients with a known hypersensitivity to levofloxacin or other quinolone drugs.[5]

Due to growing prevalence of antibiotic resistance to the fluoroquinolones in Southeast Asia, the use of levofloxacin in patients that have been to Southeast Asia is increasingly being contraindicated.[48]

Caution should be exercised in prescribing to patients with liver disease.[49]

Levofloxacin is also considered to be contraindicated in patients with epilepsy or other seizure disorders.

Pregnancy

Research indicates that the fluoroquinolones can rapidly cross the blood-placenta and blood-milk barrier, and are extensively distributed into the fetal tissues. Peak concentration in human breast milk is similar to levels attained in plasma. Breast-feeding mothers that take levofloxacin may expose their infants to severe adverse reactions, and pregnant women are at risk of spontaneous abortions and birth defects.[50][51][52] For this reason the prescribing of levofloxacin is contraindicated during pregnancy. Other flouroquinolones have also been reported as being present in the mother’s milk and are passed on to the nursing child.[53][54]

Pediatric use

Oral and I.V. Levofloxacin is not licensed for use in the pediatric population, except as noted above, due to the risk of serious, life-threatening and permanent injury to the pediatric patient. Within one study it was stated that the pediatric patient has a 3.8% chance of experiencing a serious musculoskeletal adverse event.[55]

Adverse effects that have been associated with levofloxacin use in children include musculoskeletal disorders such as arthralgia, arthritis, tendonopathy, and gait abnormality[36] The studies found within the new drug application (NDA) for levofloxacin[15] showed an adverse drug reaction (ADR) rate in excess of 40%, as well as a number of reported fatalities. However, the two most recent pediatric studies involving the use of levofloxacin, indicates that the pediatric patient has a greater than 50% chance of experiencing one or more adverse reactions. Within the first pediatric study[56] it is stated that “Of the 712 subjects evaluable for safety, 275 (52%) levofloxacin-treated subjects experienced one or more adverse event.... Serious adverse events were reported in 33 (6%) levofloxacin-treated subjects.... Two serious adverse events in levofloxacin-treated subjects resulted in fatal outcomes.” Within the second pediatric study[57] it is stated that “Of the 204 subjects evaluable for safety, 122 experienced one or more adverse events.... Twelve subjects (6%) discontinued study drug due to an adverse event.... Seven subjects (3%) experienced 8 serious adverse events.” (circa 2007)

The current ban on the use of Oral and I.V. levofloxacin and other fluoroquinolones in the pediatric population has been supported by a number of clinical studies. The evidence presented at that 62 Meeting of the Anti-Infective Drugs Advisory Committee showed that the fluoroquinolones cause irreversible joint damage in the pediatric population. The conclusion reached by this Advisory Committee was that the risk of permanent injury may outweigh the potential benefits.[39] Subsequent to this meeting, which took place in 1997, the Food and Drug Administration (FDA) has stated that it is their intention to continue to pursue the licensing of the fluoroquinolones for pediatric use in the United States, in spite of these findings.

Special precautions

Levofloxacin should be administered only as described within the Dosage Guidelines table found within the most current package insert. The status of the patient’s renal function and hepatic function must also be taken into consideration to avoid an accumulation that may lead to a fatal drug overdose. Levofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the liver and the intestine. Modification of the dosage is recommended using the table found within the package insert for those with impaired liver or kidney function (particularly for patients with severe renal dysfunction). Within the package insert, it is stated "...since the drug is known to be substantially excreted by the kidneys, the risk of toxic reactions to this drug may be greater in patients with impaired renal function."[5] The duration of treatment depends upon the severity of infection and the duration varies anywheres from 3 days to 60 days.[5]

Note: The patient’s serum levels should be monitored during therapy to avoid a drug overdose. See the most current package insert for proper dosing guidelines and relevant warnings/precautions.

Adverse effects

Serious adverse events occur more commonly with fluoroquinolones than with any other antibiotic drug classes. In most adverse reactions are mild to moderate however, occasionally serious adverse effects occur.[58][59] There have been a number of regulatory actions taken as a result of such adverse reactions, which included published warnings,[60][61][62] additional warnings and safety information added to the package inserts, which includes Black Box Warnings[63] together with the issuance of "Dear Doctor Letters"[64] concerning the recent addition of the Black Box Warnings.

In 2004 the FDA requested new warning labels to be added to all of the Fluoroquinolones, including levofloxacin, regarding peripheral neuropathy (irreversible nerve damage),[65][66] tendon damage,[67][68] Heart Problems (prolonged QT Interval / Torsades de pointes),[65][28] Pseudomembranous colitis,[69] Rhabdomyolysis (muscle wasting),[70][71][72] Stevens-Johnson Syndrome,[73] as well as concurrent usage of NSAIDs contributing to the severity of these reactions.[65]

Subsequent to this, on June 25, 2007, the FDA required the manufacturer to add an additional warning to the package inserts that stated that “Other serious and sometimes fatal events, some due to hypersensitivity, and some due to uncertain etiology, have been reported in patients receiving therapy with quinolones, including levofloxacin.”[74][75]

The serious adverse effects that may occur as a result of levofloxacin therapy include irreversible peripheral neuropathy,[66][76] spontaneous tendon rupture and tendonitis,[77][78][79][8][9] QTc prolongation/torsades de pointes,[8] toxic epidermal necrolysis (TEN)[8] and Stevens-Johnson syndrome, erythema multiforme,[80] severe central nervous system disorders (CNS), including seizures[81][82] and clostridium difficile associated disease (CDAD: Pseudomembranous colitis)[83][84][85][86] photosensitivity/phototoxicity reactions,[87][80] fatal hypoglycemia,[88] kidney damage,[89] rhabdomyolysis (muscle wasting),[70][90][91] as well as anaphylactoid reactions[92][93] and myasthenia crisis.[94]

Additional serious adverse reactions include acute pancreatitis,[95][96] temporary as well as permanent loss of vision, irreversible double vision,[97] impaired color vision, exanthema, abdominal pain, malaise, drug fever,[98] dysaesthesia and eosinophilia. Pseudotumor cerebri, commonly known as idiopathic intracranial hypertension (IIH), (also referred to as increased intracranial pressure),[99] has been reported to occur as a serious adverse reaction to levofloxacin. Another serious adverse effect is autoimmune hemolytic anemia.[100]

Older patients may have an increased risk of tendinopathy (including rupture), especially with concomitant corticosteroid use, and such patients may also be more susceptible to prolongation of the QT interval.[5] Patients with known prolongation, those with hypokalemia, or being treated with other drugs that prolong the QT interval should avoid the use of Levaquin. Hematologic reactions (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses.[5][9]

Children and the elderly are at a much greater risk of experiencing such adverse reactions.[101][102] Such reactions may manifest during, as well as long after fluoroquinolone therapy had been discontinued.[103]

Serious visual complications have also been reported to occur with ophthalmic fluoroquinolone therapy, which may also occur with levofloxacin eye drops, especially corneal perforation, but also evisceration and enucleation. This increased incidents of corneal perforation may be due to fluoroquinolones causing alterations in stromal collagen, leading to a reduction in tectonic strength.[104][105] As noted previously permanent double vision (diplopia) has also been reported.[97]

Some groups refer to these adverse events as "fluoroquinolone toxicity". These groups of people claim to have suffered serious long term harm to their health from using fluoroquinolones. This has led to a class action lawsuit by people harmed by the use of fluoroquinolones as well as legal action by the consumer advocate group Public Citizen.[106] Partly as a result of the efforts of The State of Illinois and Public Citizen the FDA ordered a black box warnings on all fluoroquinolones advising consumers of the possible toxic effects of fluoroquinolones on tendons.[107]

Overdose

In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.[5]

Pharmacology

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Chemically, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4benzoxazine-6-carboxylic acid hemihydrate. The empirical formula is C18H20FN3O4 • ½ H2O and the molecular weight is 370.38. Levofloxacin is a light yellowish-white to yellow-white crystal or crystalline powder.[5]

Some of the endogenous compounds that are affected by the levofloxacin include GABA receptors (inhibitor), OCTN2 (inhibitor)[108] blood glucose (alteration) potassium channels (in myocardial cells - inhibitor),[109] pancreatic β-cell potassium channels (inhibitor)[110] as well glutathione (depletor).

Pharmacokinetics

Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Levofloxacin is rapidly and, in essence, completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for LEVAQUIN Tablets when equal doses (mg/mg) are administered. Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.[5] Glucuronidation and hydroxylation have been cited as one of the major metabolic pathways for levofloxacin hydrochloride.[111] However the drug card for levofloxacin (DB01137) states that the biotransformation information is not available.[7] Specific information regarding biotransformation does not appear to be readily available within the package inserts. Half life is 6–8 hours.[7]

Mechanism of action

Levofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase iv,[112] which is an enzyme necessary to separate replicated DNA, thereby inhibiting cell division.

The fluoroquinolones interfere with DNA replication by inhibiting an enzyme complex called DNA gyrase. This can also affect mammalian cell replication. In particular, some congeners of this drug family display high activity not only against bacterial topoisomerases but also against eukaryotic topoisomerases, and are toxic to cultured mammalian cells and in vivo tumor models. Although the quinolone is highly toxic to mammalian cells in culture, its mechanism of cytotoxic action is not known. Quinolone-induced DNA damage was first reported in 1986.[113]

Recent studies have demonstrated a correlation between mammalian cell cytotoxicity of the quinolones and the induction of micronuclei.[114][115][116][117] As such some fluoroquinolones may cause injury to the chromosome of eukaryotic cells.[118][119][120][121][122][123]

There continues to be debate as to whether or not this DNA damage is to be considered one of the mechanisms of action concerning the severe and non-abating adverse reactions experienced by some patients following fluoroquinolone therapy.[124][125][126]

Interactions

The toxicity of drugs that are metabolised by the cytochrome P450 system is enhanced by concomitant use of some quinolones. Coadministration may dangerously increase warfarin (Coumadin) activity; INR should be monitored closely. They may also interact with the GABA A receptor and cause neurological symptoms; this effect is augmented by certain non-steroidal anti-inflammatory drugs.[127] Quercetin, a flavonol, a kind of flavonoid, occasionally used as a dietary supplement, may interact with fluoroquinolones, as quercetin competitively binds to bacterial DNA gyrase. Some foods such as garlic and apples contain high levels of quercetin; whether this inhibits or enhances the effect of fluoroquinolones is not entirely clear.[128]

Specific drug interaction studies have not been conducted with levofloxacin. However, the systemic administration of some quinolones has been shown to interfere with the metabolism of caffeine, elevate plasma concentrations of theophylline, and enhance the effects of the warfarin and its derivatives. In patients receiving systemic cyclosporine concomitantly, transient elevations in serum creatinine has been noted.[7]

Significant drug interactions

Levofloxacin has been reported to interact with a significant number of other drugs, as well as a number of herbal and natural supplements. Such interactions increased the risk of cardiotoxicity and arrhythmias, anticoagulant effects, the formation of non-absorbable complexes, as well as increasing the risk of toxicity.

Some drug interactions are associated with molecular structural modifications of the quinolone ring, specifically interactions involving NSAIDS and theophylline. The fluoroquinolones have also been shown to interfere with the metabolism of caffeine[129] and the absorption of levothyroxine. The interference with the metabolism of caffeine may lead to the reduced clearance of caffeine and a prolongation of its serum half-life, resulting in a caffeine overdose. Ciprofloxacin has been shown to interact with thyroid medications (levothyroxine) resulting in unexplained hypothyroidism.[130] As such it is possible that levofloxacin may interact with thyroid medications as well.

The use of NSAIDs (Non-Steroid Anti-Inflammatory Drugs) while undergoing fluoroquinolone therapy is contraindicated due to the risk of severe CNS adverse reactions, including but not limited to seizure disorders. Fluoroquinolones with an unsubstituted piperazinyl moiety at position 7 have the potential to interact with NSAIDs and/or their metabolites, resulting in antagonism of GABA neurotransmission.[131] Whether or not such reactions occur after completion of therapy is unclear. Patients have reported reactions to NSAIDS long after completion of fluoroquinolone therapy, but there does not appear to be any research that would either confirm or deny this association other than these anecdotal reports.

Some quinolones exert an inhibitory effect on the cytochrome P-450 system, thereby reducing theophylline clearance and increasing theophylline blood levels. Coadministration of certain fluoroquinolones and other drugs primarily metabolized by CYP1A2 (e.g., theophylline, methylxanthines, tizanidine) results in increased plasma concentrations and could lead to clinically significant side effects of the coadministered drug. In addition, other fluoroquinolones, especially enoxacin, and to a lesser extent ciprofloxacin and pefloxacin, also inhibit the metabolic clearance of theophylline.[132]

Such drug interactions appear to be related to the structural changes of the quinolone ring and the inhibitory effect on the cytochrome P-450 system. As such, these drug interactions involving the fluoroquinolones appear to be drug-specific rather than a class effect.

Current or past treatment with oral corticosteroids is associated with an increased risk of Achilles tendon rupture, especially in elderly patients also taking the fluoroquinolones. This effect seems to be restricted to people aged 60 or over and within this group concomitant use of corticosteroids increases this risk substantially.[67][133]

Additional regulatory history in the United States

Levofloxacin was first patented in 1987, and was subsequently approved for use in Japan (October 1, 1993), Korea (April 4, 1994), Hong Kong (October 3, 1994), and China (May 3, 1995). Levofloxacin received FDA approval in the United States December 20, 1996. Floxin (ofloxacin – floxacin) was patented in 1982 (European patent Daiichi) and received FDA approval December 28, 1990. The U.S. patent is owned by Daiichi Sankyo and exclusively licensed to Ortho-McNeil.[134][15]

Many of the clinical isolates that were initially tested within the NDA for levofloxacin against Floxin (ofloxacin –floxacin) disks instead of levofloxacin disks but reported as susceptible or resistant to levofloxacin. When levofloxacin disks were not available in early clinical trials, a 5-pg Floxin (ofloxacin –floxacin) disk was substituted. The FDA medical reviewers considered the two drugs to be one and the same and hence interchangeable.[15]

The FDA requested updating the carton and container labels to include a statement to let dispensers know that a Medication Guide must be dispensed with the product, in compliance with the Medication Guide Regulations as specified in 21 CFR 208.24 (d).

Issuance of a Medication Guide and revisions to include new safety information. The FDA has determined that levofloxacin poses a serious and significant public health concern, requiring the distribution of a Medication Guide. However the Medication Guide does not include any Black Box Warnings.[137]

Note: Although the FDA had requested that the revised labeling (which were to include the Black Box Warnings)[138] accompany the package inserts for any newly shipped products (effective January 2009) there are continuing reports that as of July 2009, that the products continue to contain the older labels, and not the revised labels, and that the Medication Guides (absent of the Black Box Warnings) were not made available for distribution.

History of the black box warnings

Musculoskeletal disorders attributed to use of quinolone antibiotics were first reported in the medical literature in 1972, as an adverse reaction to nalidixic acid.[139] Rheumatic disease after use of a fluoroquinolone (norfloxacin) was first reported eleven years later.[140] In a 1995 letter published in the New England Journal of Medicine, representatives of the U.S. Food and Drug Administration (FDA) stated that the agency would "update the labeling [package insert] for all marketed fluoroquinolones to include a warning about the possibility of tendon rupture."[141]

By August 1996, the FDA had not taken action, and the consumer advocacy group Public Citizen filed a petition with the FDA prompting the agency to act.[142] Two months later, the FDA published an alert in the FDA Medical Bulletin and requested that fluoroquinolone package inserts be amended to include information on this risk.[143]

In 2005, the Illinois Attorney General filed a petition with the FDA, seeking black box warnings and "Dear Doctor" letters emphasizing the risk of tendon rupture; the FDA responded that it had not yet been able to reach a decision on the matter.[144] In 2006, Public Citizen, supported by the Illinois Attorney General, renewed its demand of ten years prior for a black box warning.[144][145] In January 2008, Public Citizen filed suit to compel the FDA to respond to their 2006 petition.[146][147] On July 7, the FDA ordered the makers of systemic-use fluoroquinolones to add a boxed warning regarding tendon rupture, and to develop a Medication Guide for patients.[148][149] The package inserts for Cipro (ciprofloxacin), Avelox (moxifloxacin), Proquin XR, Factive (gemifloxacin), Floxin (ofloxacin), Noroxin (norfloxacin) and Levaquin (levofloxacin) were amended on September 8, 2008 to include these new warnings.[63] Bayer, which manufactures Cipro, Avelox and Proquin XR, issued a Dear Healthcare Professional letter on October 22 concerning these changes.[150] Ortho-McNeil, the manufacturers of Levaquin, issued a similar letter in November.[64] through the Health Care Notification Network, a registration-only website that distributes drug alerts to licensed healthcare professionals.

Review of the FDA website indicates that the majority of the generic versions of the fluoroquinolones have not been updated to include this Black Box Warning as of July 2009. And there are numerous reports that this information has not been dessiminated to the pharmacist, the products continue to contain the previous labels that are absent of this warning, and the Medication Guide has not been made available to the pharmicist or physician for distribution.

Antibiotic abuse and bacterial resistance

See also: Antibiotic abuse and Antibiotic resistance

Resistance to levofloxacin and other fluoroquinolones may evolve rapidly, even during a course of treatment. Numerous pathogens, including Staphylococcus aureus, enterococci, and Streptococcus pyogenes now exhibit resistance worldwide.[151] There are three known mechanisms of resistance. Some types of efflux pumps can act to decrease intracellular quinolone concentration. In gram-negative bacteria, plasmid-mediated resistance genes produce proteins that can bind to DNA gyrase, protecting it from the action of quinolones. Finally, mutations at key sites in DNA gyrase or Topoisomerase IV can decrease their binding affinity to quinolones, decreasing the drug's effectiveness.[152]

Years ago, the FDA had added warnings regarding the proper use of Levaquin within the package inserts to combat such prescription abuse. Advising physicians that levofloxacin: "...should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria...."[75]

"Normally levofloxacin should only be used in patients who have failed at least one prior therapy. Reserved for the use in patients who are seriously ill and may soon require immediate hospitalization."(sic)[153] Though considered to be a very important and necessary drug required to treat severe and life-threatening bacterial infections, the associated prescription abuse of levofloxacin remains unchecked, which has contributed to the problem of bacterial resistance. The overuse of antibiotics, such as happens with children suffering from otitis media, has given rise to a breed of super-bacteria that are resistant to antibiotics entirely.[154]

Fluoroquinolones, including levofloxacin, had become the most commonly prescribed class of antibiotics to adults in 2002. Nearly half (42%) of these prescriptions were for conditions not approved by the FDA, such as acute bronchitis, otitis media, and acute upper respiratory tract infection, according to a study that was supported in part by the Agency for Healthcare Research and Quality.[155][156] In addition, they are commonly prescribed for medical conditions that are not even bacterial to begin, with such as viral infections, or those to which no proven benefit exists.

Social and economic impact

See also: Quinolone#Social and economic impact

The adverse drug reaction profile of levofloxacin and other fluoroquinolone drugs has spawned a grass root movement of those so affected to lobby for Black Box Warnings and Dear Doctor Letters as well as the petitioning of the FDA for the removal of some fluoroquinolone drugs from clinical practice.[142][145][157][158][159][160]

Patent extensions

Under the Bush administration (2001–2008), patent extension legislation was signed into law that allowed Johnson and Johnson–Ortho McNeil, as well as other drug companies, a six-month patent extension for testing their products for safety in children. Johnson and Johnson–Ortho McNeil will earn hundreds of millions of dollars due to the FDA's recently granting pediatric exclusivity for Levaquin, as this extends their patent monopoly till the end of 2010. The legislation that was signed by President Bush, granting Johnson and Johnson–Ortho McNeil and other drug manufacturers a six-month extension on their patents (to conduct pediatric testing), was drafted after extensive lobbying of numerous members of Congress by Bayer A.G., Johnson and Johnson–Ortho McNeil, and others. One of the four sponsors of this legislation was Chris Dodd (D-CT), who, at the time, ranked as one of the top three beneficiaries of campaign contributions by drug companies. Sen. Edward Kennedy (D-Mass.), who chaired the committee with jurisdiction over the bill, refused to fight over the language that (if it had been included) would have reduced the drug company's profits due to these patent extensions. The reasons for Sen. Edward Kennedy's decision not to fight for the inclusion of this language were not made known.[161]

The results of these pediatric trials involving levofloxacin included two reported pediatric fatalities that the investigators determined were not related to the drug.[56] Within one study it was stated that the pediatric patient has a 3.8% chance of experiencing a serious musculoskeletal adverse event.[162] However, the two most recent pediatric studies involving the use of levofloxacin, indicates that the pediatric patient has a greater than 50% chance of experiencing one or more adverse reactions, which would be consistent with the studies found within the NDA (new drug application) for levofloxacin,[15] which showed an ADR rate in excess of 40%, as well as a number of reported fatalities. Within the first study,[56] it is stated that “Of the 712 subjects evaluable for safety, 275 (52%) levofloxacin-treated subjects experienced one or more adverse event.... Serious adverse events were reported in 33 (6%) levofloxacin-treated subjects.... Two serious adverse events in levofloxacin-treated subjects resulted in fatal outcomes.” Within the second study[163] it is stated that “Of the 204 subjects evaluable for safety, 122 experienced one or more adverse events.... Twelve subjects (6%) discontinued study drug due to an adverse event.... Seven subjects (3%) experienced 8 serious adverse events.” (circa 2007)

Generic equivalents

In 2005, the US Court of Appeals for the Federal Circuit had affirmed the validity of US patent (No. 5,053,407) on levofloxacin, held by Daiichi Sankyo Co., Ltd. On October 17, 2006, Daiichi Sankyo also won a patent infringement lawsuit in Canada involving the generic version of Levaquin. The Canadian Federal Appeals Court upheld a lower court's ruling handed down last October, which accepted the validity of Daiichi Sankyo's patent until June 23, 2009. Daiichi Sankyo and Janssen-Ortho Inc., a Johnson & Johnson subsidiary, filed a lawsuit with a federal court in Toronto after Teva Novopharm Ltd., started selling the generic version of levofloxacin in December 2004. The Canadian Federal Court in Toronto ordered Novopharm to suspend selling the generic version of the drug. Unsatisfied with the ruling, Novopharm appealed to the higher court.[26] On June 7, 2007, the Canadian Federal Appeal Court dismissed this appeal. Novopharm was prevented from making, using, offering to sell, or selling a generic version of levofloxacin tablets in the Canadian market until the expiration of patent on June 23, 2009. Novopharm's generic version of Levaquin, had been sold in Canada since 2004.

Current litigation

An official complaint has been filed by The US Justice Department with a Federal Court in Boston (January 2010) accusing Johnson and Johnson of illegally paying millions of dollars in kickbacks to Omnicare, one of the nation's largest pharmacies specializing in nursing home patients. In return, Omnicare nearly tripled its annual purchase of Johnson and Johnson’s products; including Levaquin. The sales of Levaquin overtook other leading medications like Ciprofloxacin over a five year period between 1999 and 2004. These sales increased dramatically despite the growing reports concerning the severe adverse reactions associated with such therapy in the elderly.[164][165][166]

There is also a significant number of cases currently pending before the United States District Court, District of Minnesota, involving Levaquin. On June 13, 2008, a Judicial Panel On Multidistrict Litigation (MDL) granted the Plaintiffs’ motion to centralize individual and class action lawsuits involving Levaquin in the District of Minnesota over objection of Defendants, Johnson and Johnson / Ortho McNeil.[167] On July 6, 2009, The New Jersey Supreme Court had also designated litigation over Levaquin as a mass tort and has assigned it to an Atlantic County, N.J., judge. The suits charge that the drug has caused achilles tendon ruptures and other permanent damage.[168] Additional lawsuits have also been recently filed in the Illinois State Court (September 2009) by a national law firm based in St. Louis currently investigating over 1,200 potential claims alleging that Johnson & Johnson and Ortho-McNeil Pharmaceutical Inc. tried to thwart early efforts to warn patients of the risks by manipulating study data and that they downplayed the risks to physicians.[169]

On April 8, 2010 in the Beaumont Division of the Eastern District of Texas, a class action lawsuit was filed by Lisa Presley on behalf of herself and others similar situated against Johnson and Johnson, Ortho-McNeil Pharmaceuticals Inc. and Johnson and Johnson Pharmaceutical Research and Development LLC. (Case No 1:10cv00200.) This class action lawsuit was filed in regards to the severe and permanent adverse reactions associated with levaquin therapy.[170]

The various manufacturers have countered these allegations stating that they believe that these drugs are both safe and effective antibiotics, well tolerated with a minimum of side-effects, that such reactions are “rare” and the benefits of such therapy outweigh the perceived risks.[171]

Several class action lawsuits had been filed in regards to the adverse reactions suffered by those exposed to ciprofloxacin during the anthrax scare of 2001, as well.[172][173][174]

Package insert links

See also

References

  1. ↑ Nelson, JM.; Chiller, TM.; Powers, JH.; Angulo, FJ. (Apr 2007). "Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story.". Clin Infect Dis 44 (7): 977–80. doi:10.1086/512369. PMID 17342653. 
  2. ↑ Kawahara, S. (Dec 1998). "[Chemotherapeutic agents under study]". Nippon Rinsho 56 (12): 3096–9. PMID 9883617. 
  3. ↑ Liu, H.; Mulholland, SG. (July 2005). "Appropriate antibiotic treatment of genitourinary infections in hospitalized patients.". Am J Med 118 Suppl 7A: 14S–20S. doi:10.1016/j.amjmed.2005.05.009. PMID 15993673. 
  4. ↑ MacDougall C, Guglielmo BJ, Maselli J, Gonzales R (March 2005). "Antimicrobial drug prescribing for pneumonia in ambulatory care". Emerging Infect. Dis. 11 (3): 380–4. PMID 15757551. http://www.cdc.gov/ncidod/EID/vol11no03/04-0819.htm. 
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 Janssen Pharmaceutica (September 2008). "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf. 
  6. ↑ Morrissey, I.; Hoshino, K.; Sato, K.; Yoshida, A.; Hayakawa, I.; Bures, MG.; Shen, LL. (August 1996). "Mechanism of differential activities of ofloxacin enantiomers." (PDF). Antimicrob Agents Chemother 40 (8): 1775–84. PMID 8843280. PMC 163416. http://aac.asm.org/cgi/reprint/40/8/1775.pdf. 
  7. ↑ 7.0 7.1 7.2 7.3 DrugBank (19 February 2009). "Showing drug card for Levofloxacin (DB01137)". Canada. http://www.drugbank.ca/drugs/DB01137. 
  8. ↑ 8.0 8.1 8.2 8.3 Renata Albrecht (19 June 2007). "NDA 20-634/S-045, NDA 20-635/S-048, NDA 21-721/S-013" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/020634s045,%20020635s048,%20021721s013ltr.pdf. 
  9. ↑ 9.0 9.1 9.2 Renata Albrecht (16 April 2008). "NDA 20-634/S-051, NDA 20-635/S-055, NDA 21-721/S-019" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/020634s051,%20020635s055,%20021721s019ltr.pdf. 
  10. ↑ University of Maryland Medical Center. "Levofloxacin". USA: University of Maryland. http://www.umm.edu/altmed/drugs/levofloxacin-075755.htm#U.S.%20Brand%20Names. 
  11. ↑ Takashi Shoda (23 October 2008). "UK Levofloxacin SPC and Underlying Patent Upheld by High Court Patent Court". USA: Daiichi Sankyo, Limited. http://www.daiichisankyo.com/news/yymmdd_nn.html?b_newsrelease_n1_eng.detail%5Bid%5D=682.3&b_newsrelease_n1_eng.year_selector%5Bid%5D=682.3&b_newsrelease_n1_eng.category_selector%5Bid%5D=682.3. 
  12. ↑ Johnson & Johnson (2009). [http://files.shareholder.com/downloads/JNJ/0x0x171267/057640f8-b2c0-4b0f-9f54-7a24a553c3ce/2007AR.pdf "Analysis of Sales by Business Segments"] (PDF). Shareholder. p. 27. http://files.shareholder.com/downloads/JNJ/0x0x171267/057640f8-b2c0-4b0f-9f54-7a24a553c3ce/2007AR.pdf. 
  13. ↑ 13.0 13.1 13.2 "LEVAQUIN". USA: drugpatentwatch.com. http://www.drugpatentwatch.com/premium/preview/detail/index.php?searchtype=alpha&category=Tradename&searchstring=LEVAQUIN. 
  14. ↑ Ed Lamb (1 May 2008). "Top 200 Prescription Drugs of 2007". USA: Pharmacy Times. http://www.pharmacytimes.com/issues/articles/2008-05_003.asp. 
  15. ↑ 15.0 15.1 15.2 15.3 15.4 R.W. Johnson (20 December 1996). "Levaquin (Levofloxacin) NDA 20634". USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020634_levaquin_toc.cfm. 
  16. ↑ "Levofloxacin.". Tuberculosis (Edinb) 88 (2): 119–21. March 2008. doi:10.1016/S1472-9792(08)70013-1. PMID 18486047. 
  17. ↑ North DS, Fish DN, Redington JJ (1998). "Levofloxacin, a second-generation fluoroquinolone". Pharmacotherapy 18 (5): 915–35. PMID 9758306. 
  18. ↑ Lemke, Thomas L.; Williams, David A. (1 October 2007). Foye's Principles of Medicinal Chemistry (6 ed.). USA: Lippincott Williams & Wilkins. ISBN 978-0781768795. http://books.google.com/?id=NHQQBMM-qMEC&pg=PP1. 
  19. ↑ "Levaquin Information". USA: Medications.com. http://www.medications.com/drugs/levaquin. 
  20. ↑ King DE, Malone R, Lilley SH (May 2000). "New classification and update on the quinolone antibiotics". American Family Physician 61 (9): 2741–8. PMID 10821154. http://www.aafp.org/afp/20000501/2741.html. Retrieved 2009-06-30. 
  21. ↑ Davis R, Bryson HM (April 1994). "Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy". Drugs 47 (4): 677–700. doi:10.2165/00003495-199447040-00008. PMID 7516863. 
  22. ↑ "STATISTICAL REVIEW AND EVALUATION" (PDF). USA: FDA. 21 November 1996. http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020634-4.pdf. 
  23. ↑ Ed Lamb (1st May 2008). "Top 200 Prescription Drugs of 2007". Pharmacy Times. http://www.pharmacytimes.com/issues/articles/2008-05_003.asp. Retrieved 21 July 2009. 
  24. ↑ Cravit, Cravit Ophthalmic, Elequine, Floxel, Iquix, Leroxacin, Lesacin, Levaquin, Levokacin, Levox, Levoxacin, Mosardal, Nofaxin, Quixin, Reskuin, Tavanic, Volequin http://www.drugbank.ca/drugs/DB01137
  25. ↑ Cravox, Floxlevo, Levoxacine, Levoxetina, Nislev, Oftaquix , Prixar, Reskuin, Tavanic source: http://www.umm.edu/altmed/drugs/levofloxacin-075755.htm#International%20Brand%20Names
  26. ↑ 26.0 26.1 "Novopharm Limited". USA. 3 November 2009. http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=4240255. 
  27. ↑ Mark J. Goldberger (17 December 1998). "Center for drug evaluation and research" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020634s04_appltr.pdf. 
  28. ↑ 28.0 28.1 Mark J. Goldberger. "NDA 20-634/S-008, S-009, NDA 20-635/S-007, S-008" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20635S7,8LTR.PDF. 
  29. ↑ Renata Albrecht,. "NDA 20-634/S-013, NDA 20-635/S-010" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20635S10ltr.pdf. 
  30. ↑ Renata Albrecht. "NDA 20-634/S-025, NDA 20-635/S-022" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20634se1-025,20635se1-022ltr.pdf. 
  31. ↑ Renata Albrecht (23 May 2003). "NDA 20-634/S-027, NDA 20-635/S-026" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/20634se1-027,20635se1-026ltr.pdf. 
  32. ↑ Nickel, JC.; Downey, J.; Clark, J.; Casey, RW.; Pommerville, PJ.; Barkin, J.; Steinhoff, G.; Brock, G. et al. (October 2003). "Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial.". Urology 62 (4): 614–7. doi:10.1016/S0090-4295(03)00583-1. PMID 14550427. 
  33. ↑ Renata Albrecht (24 November 2004). "NDA 20-634/S-035, NDA 20-635/S-035, NDA 21-721/S-003" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20634s035,20635s035,21721s003ltr.pdf. 
  34. ↑ Renata Albrecht (8 April 2005). "NDA 20-634/S-037, NDA 20-635/S-038, NDA 21-721/S-002" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/020634s037,020635s038,021721s002ltr.pdf. 
  35. ↑ 35.0 35.1 35.2 Renata Albrecht (23 June 2006). "NDA 20-634/S-040, NDA 20-635/S-043, NDA 21-721/S-007" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/020634s040,020635s043,021721s007LTR.pdf. 
  36. ↑ 36.0 36.1 Renata Albrecht (5 May 2008). "NDA 20-634/S-047, NDA 20-635/S-051, NDA 21-721/S-015" (FDA). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/020634se5-047020635se5-051021721se5-015ltr.pdf. 
  37. ↑ John A. Bosso (1998). "New and Emerging Quinolone Antibiotics". Journal of Infectious Disease Pharmacotherapy 2 (4): 61–76. doi:10.1300/J100v02n04_06. ISSN 1068-7777. http://bubl.ac.uk/archive/journals/jidp/v02n0498.htm#6new. 
  38. ↑ "SYNOPSIS" (PDF). veritasmedicine.com. 6 September 2005. http://download.veritasmedicine.com/PDF/CR002392_CSR.pdf. 
  39. ↑ 39.0 39.1 39.2 DAVID C. VAN SICKLE; BARTH RELLER, JON S. ABRAMSON, IRENE BIDAULT, JOHN S. BRADLEY et, al. (19 November 1996). "ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE 62nd MEETING" (PDF). USA: FDA. http://fqresearch.org/pdf_files/62nd_fda_meeting.pdf. "One interesting case that is not included on this slide for arthralgias was a 15-year-old boy who received ofloxacin IV for an emergency appendectomy and had not grown more than his 70 inches in height over the last year. The 15th percentile for height for a 15-year-old boy, however, is 66.5 inches, and the expected growth rate is about two inches per year…The third case is articular. It is a 17-year-old patient who experienced arthropathy, and the drug was not suspected and the treatment was continued two following months. It leads to destructive arthropathy of the knees and the hip, and prothesis was performed three years later. If an irreversible cartilaginous lesion can occur, it is very likely that is going to cause problems down the line and we can't even anticipate what they are like…" 
  40. ↑ 40.0 40.1 Dolui SK, Das M, Hazra A (2007). "Ofloxacin-induced reversible arthropathy in a child". Journal of Postgraduate Medicine 53 (2): 144–5. doi:10.4103/0022-3859.32220. PMID 17495385. 
  41. ↑ Division of Special Pathogen and Immunologic Drug Products Summary of Clinical Review of Studies Submitted in Response to a Pediatric Written Request
  42. ↑ Chalumeau M, Tonnelier S, D'Athis P (June 2003). "Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France". Pediatrics 111 (6 Pt 1): e714–9. doi:10.1542/peds.111.6.e714. PMID 12777590. http://pediatrics.aappublications.org/cgi/content/full/111/6/e714. Retrieved 2009-06-29. 
  43. ↑ "SYNOPSIS" (PDF). veritasmedicine.com. http://download.veritasmedicine.com/PDF/CR002392_CSR.pdf. 
  44. ↑ "SYNOPSIS" (PDF). veritasmedicine.com. http://download.veritasmedicine.com/PDF/CR002389_CSR.pdf. 
  45. ↑ "SYNOPSIS" (PDF). USA: veritasmedicine.com. http://download.veritasmedicine.com/PDF/CR002389_CSR.pdf. 
  46. ↑ Shepard CW, Soriano-Gabarro M, Zell ER (October 2002). "Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence". Emerging Infectious Diseases 8 (10): 1124–32. PMID 12396927. PMC 2730317. http://www.cdc.gov/ncidod/EID/vol8no10/02-0349.htm. Retrieved 2009-06-30. 
  47. ↑ "DOHMH ALERT #8:Fluoroquinolone-resistant gonorrhea, NYC". NY County Medical Society. 2004-04-30. http://www.nycms.org/article_view.php3?view=947&part=1. Retrieved 2009-06-30. 
  48. ↑ Centers for Disease Control and Prevention (CDC) (October 1995). "Fluoroquinolone resistance in Neisseria gonorrhoeae—Colorado and Washington, 1995". MMWR Morb Mortal Wkly Rep. 44 (41): 761–4. PMID 7565558. http://www.cdc.gov/mmwr/preview/mmwrhtml/00039305.htm. 
  49. ↑ Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I (October 2005). "Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection". Ann Pharmacother 39 (10): 1737–40. doi:10.1345/aph.1G111. PMID 16105873. 
  50. ↑ Cahill JB, Bailey EM, Chien S, Johnson GM (January 2005). "Levofloxacin secretion in breast milk: a case report". Pharmacotherapy 25 (1): 116–8. doi:10.1592/phco.25.1.116.55616. PMID 15767227. 
  51. ↑ Nardiello S, Pizzella T, Ariviello R (March 2002). "[Risks of antibacterial agents in pregnancy"] (in Italian). Le Infezioni in Medicina 10 (1): 8–15. PMID 12700435. http://www.infezmed.it/VisualizzaUnArticolo.aspx?Anno=2002&numero=1&ArticoloDaVisualizzare=Vol_10_1_2002_1. Retrieved 2009-06-30. 
  52. ↑ Loebstein R, Addis A, Ho E (June 1998). "Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study". Antimicrobial Agents and Chemotherapy 42 (6): 1336–9. PMID 9624471. 
  53. ↑ Shin HC, Kim JC, Chung MK (September 2003). "Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats". Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136 (1): 95–102. doi:10.1016/j.cca.2003.08.004. PMID 14522602. 
  54. ↑ Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H (February 1993). "Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women". Antimicrob. Agents Chemother. 37 (2): 293–6. PMID 8452360. 
  55. ↑ Noel GJ, Bradley JS, Kauffman RE (October 2007). "Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders". Pediatr. Infect. Dis. J. 26 (10): 879–91. doi:10.1097/INF.0b013e3180cbd382. PMID 17901792. 
  56. ↑ 56.0 56.1 56.2 "SYNOPSIS". USA. http://download.veritasmedicine.com/PDF/CR002392_CSR.pdf. Retrieved 29 January 2009. 
  57. ↑ "SYNOPSIS". USA. http://download.veritasmedicine.com/PDF/CR002389_CSR.pdf. Retrieved 29 January 2009. 
  58. ↑ Owens Rc, Jr; Ambrose, PG (July 2005). "Antimicrobial safety: focus on fluoroquinolones.". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 41 Suppl 2: S144–57. doi:10.1086/428055. ISSN 1058-4838. PMID 15942881. 
  59. ↑ De Sarro A, De Sarro G (March 2001). "Adverse reactions to fluoroquinolones. an overview on mechanistic aspects" (PDF). Curr. Med. Chem. 8 (4): 371–84. PMID 11172695. http://www.fqresearch.org/pdf_files/cmc.pdf. 
  60. ↑ http://www.fqresearch.org/text_documents/FDA_Medical_Bulletin_1996.doc
  61. ↑ U S Food and Drug Administration (8 July 2008). "FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs" (PDF). USA: FDA. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116919.htm. Retrieved 5 September 2009. 
  62. ↑ US Food and Drug Administration (2008). "Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin and generic ofloxacin)"]. USA. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084316.htm. Retrieved 5 September 2009. 
  63. ↑ 63.0 63.1 US Food and Drug Administration. "Drugs at FDA: FDA Approved Drug Products". USA: FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Retrieved 5 September 2009. 
  64. ↑ 64.0 64.1 Rosenthal, Norman (November 2008). "Important Change in the LEVAQUIN (Ievofloxacin) Complete Prescribing Information -Addition of Boxed Warning and Medication Guide Regarding Tendinitis and Tendon Rupture". Ortho-McNeil Janssen Scientific Affairs, LLC. http://www.fqresearch.org/pdf_files/Levaquin_11_2008_ortho_mcneil_dear_dr_letter.pdf. Retrieved 2008-12-27. 
  65. ↑ 65.0 65.1 65.2 Renata Albrecht (14 September 2004). "NDA 20-634/S-033, S-034, NDA 20-635/S-033, S-034" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20634s033,034,20635s033,034ltr.pdf. 
  66. ↑ 66.0 66.1 Renata Albrecht (14 July 2004). "NDA 19-537/S-053, S-054, NDA 20-780/S-017, S-018" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19537s053,054,20780s017,018ltr.pdf. Retrieved 5 September 2009. 
  67. ↑ 67.0 67.1 Renata Albrecht (18 December 2001). "NDA 20-634/S-015, S-021, S-022, NDA 20-635/S-012, S-019, S-020" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/20634s15s21s22ltr.pdf. 
  68. ↑ Renata Albrecht (4 November 2004). "NDA 20-634/S-036, NDA 20-635/S-037" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20635s037,20634s036ltr.pdf. 
  69. ↑ http://www.fqresearch.org/pub_med_levaquin/clostridum_difficicile_pub_med_levaquin.doc
  70. ↑ 70.0 70.1 Petitjeans, F.; Nadaud, J.; Perez, JP.; Debien, B.; Olive, F.; Villevieille, T.; Pats, B. (December 2003). "A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin.". Eur J Clin Pharmacol 59 (10): 779–80. doi:10.1007/s00228-003-0688-x. PMID 14576967. 
  71. ↑ Hsiao, SH.; Chang, CM.; Tsao, CJ.; Lee, YY.; Hsu, MY.; Wu, TJ. (January 2005). "Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy.". Ann Pharmacother 39 (1): 146–9. doi:10.1345/aph.1E285. PMID 15562138. 
  72. ↑ Korzets, A.; Gafter, U.; Dicker, D.; Herman, M.; Ori, Y. (November 2006). "Levofloxacin and rhabdomyolysis in a renal transplant patient.". Nephrol Dial Transplant 21 (11): 3304–5. doi:10.1093/ndt/gfl396. PMID 16968728. 
  73. ↑ Renata Albrecht (31 May 2007). "NDA 20-634/S-042, NDA 20-635/S-045, NDA 21-721/S-010" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/020634s042,020635s045,021721s010ltr.pdf. 
  74. ↑ Renata Albrecht (19 June 2006). "NDA 19-537/S-062, NDA 20-780/S-023, NDA 19-847/S-037, NDA 19-857/S-042, NDA 21-473/S-016" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/019537s62,020780s23,019847s37,019857s42,021473s16LTR.pdf. Retrieved 5 September 2009. 
  75. ↑ 75.0 75.1 Renata Albrecht (5 March 2004). "NDA 20-634/S-029, NDA 20-635/S-029" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20634slr029,20635slr029ltr.pdf. 
  76. ↑ Cohen JS (December 2001). "Peripheral Neuropathy Associated with Fluoroquinolones" (PDF). Ann Pharmacother 35 (12): 1540–7. doi:10.1345/aph.1Z429. PMID 11793615. http://fqvictims.org/fqvictims/News/neuropathy/Neuropathy.pdf. 
  77. ↑ Renata Albrecht (15 March 2004). "NDA 19-537/S-048, S-050, S-051 NDA 20-780/S-012, S-014, S-015" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19537slr048,050,051,20780slr012,014,015ltr.pdf. Retrieved September 2009. 
  78. ↑ Renata Albrecht (3 October 2008). "NDA 20-634/S-052, NDA 20-635/S-057, NDA 21-721/S-020" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/020634s052,%20020635s057,021721s020ltr%20.pdf. 
  79. ↑ Renata Albrecht (3 October 2008). "NDA 19-537/S-068, NDA 19-847/S-042, NDA 19-857/S-049, NDA 20-780/S-026, NDA 21-473/S-024" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/019537s068,019847s042ltr.pdf. Retrieved 5 September 2009. 
  80. ↑ 80.0 80.1 Renata Albrecht (13 December 2007). "NDA 20-634/S-050, NDA 20-635/S-054, NDA 21-721/S-018" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/020634s050,%20020635s054,%20021721s018ltr.pdf. 
  81. ↑ Kushner, JM.; Peckman, HJ.; Snyder, CR. (October 2001). "Seizures associated with fluoroquinolones.". Ann Pharmacother 35 (10): 1194–8. doi:10.1345/aph.10359. PMID 11675843. 
  82. ↑ http://www.fqresearch.org/pub_med_levaquin/seizures_pub_med_levaquin.doc
  83. ↑ Ozawa, TT.; Valadez, T. (March 2002). "Clostridium difficile infection associated with levofloxacin treatment.". Tenn Med 95 (3): 113–5. PMID 11898264. 
  84. ↑ Gopal Rao, G.; Mahankali Rao, CS.; Starke, I. (March 2003). "Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy.". J Antimicrob Chemother 51 (3): 697–701. doi:10.1093/jac/dkg115. PMID 12615873. 
  85. ↑ Muto CA, Pokrywka M, Shutt K (March 2005). "A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use". Infect Control Hosp Epidemiol 26 (3): 273–80. doi:10.1086/502539. PMID 15796280. http://www.journals.uchicago.edu/doi/pdf/10.1086/502539. 
  86. ↑ Deshpande, A.; Pant, C.; Jain, A.; Fraser, TG.; Rolston, DD. (February 2008). "Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence.". Curr Med Res Opin 24 (2): 329–33. doi:10.1185/030079908X253735. PMID 18067688. 
  87. ↑ Cho, S.; Breedlove, JJ.; Gunning, ST. (January 2008). "Radiation recall reaction induced by levofloxacin.". J Drugs Dermatol 7 (1): 64–7. PMID 18246700. 
  88. ↑ http://www.fqresearch.org/pub_med_levaquin/hypoglycemia_pib_med_levaquin.doc
  89. ↑ http://www.fqresearch.org/pub_med_levaquin/kidney_damage_pub_med_levaquin.doc
  90. ↑ Hsiao, SH.; Chang, CM.; Tsao, CJ.; Lee, YY.; Hsu, MY.; Wu, TJ. (January 2005). "Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy.". Ann Pharmacother 39 (1): 146–9. doi:10.1345/aph.1E285. PMID 15562138. 
  91. ↑ Korzets, A.; Gafter, U.; Dicker, D.; Herman, M.; Ori, Y. (November 2006). "Levofloxacin and rhabdomyolysis in a renal transplant patient.". Nephrol Dial Transplant 21 (11): 3304–5. doi:10.1093/ndt/gfl396. PMID 16968728. 
  92. ↑ Smythe, MA.; Cappelletty, DM. (December 2000). "Anaphylactoid reaction to levofloxacin.". Pharmacotherapy 20 (12): 1520–3. doi:10.1592/phco.20.19.1520.34868. PMID 11130225. 
  93. ↑ Takahama, H.; Tsutsumi, Y.; Kubota, Y. (September 2005). "Anaphylaxis due to levofloxacin.". Int J Dermatol 44 (9): 789–90. doi:10.1111/j.1365-4632.2004.02325.x. PMID 16135155. 
  94. ↑ Gunduz, A.; Turedi, S.; Kalkan, A.; Nuhoglu, I. (August 2006). "Levofloxacin induced myasthenia crisis.". Emerg Med J 23 (8): 662. doi:10.1136/emj.2006.038091. PMID 16858118. PMC 2564188. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564188/?tool=pubmed. 
  95. ↑ Mennecier, D.; Thiolet, C.; Bredin, C.; Potier, V.; Vergeau, B.; Farret, O. (October 2001). "[Acute pancreatitis after treatment by levofloxacin and methylprednisolone]". Gastroenterol Clin Biol 25 (10): 921–2. PMID 11852403. 
  96. ↑ Domínguez Jiménez, JL.; Bernal Blanco, E.; Marín Moreno, MA.; Puente Gutiérrez, JJ. (April 2009). "[Acute pancreatitis associated with levofloxacin"] (in Spanish). Gastroenterol Hepatol 32 (4): 323–4. doi:10.1016/j.gastrohep.2008.09.027. PMID 19371975. http://www.elsevier.es/revistas/ctl_servlet?_f=7064&ip=94.7.35.23&articuloid=13136637&revistaid=14. 
  97. ↑ 97.0 97.1 Fraunfelder, FW.; Fraunfelder, FT. (September 2009). "Diplopia and fluoroquinolones.". Ophthalmology 116 (9): 1814–7. doi:10.1016/j.ophtha.2009.06.027. PMID 19643481. 
  98. ↑ Grépinet, C.; Guillocheau, E.; Berteloot, A.; Vachée, A.; Herbin, O.; Gautier, S.; l'association des centres régionaux de pharmacovigilance (2008). "[Drug-induced fever during treatment with levofloxacin: a case-report]". Therapie 63 (4): 341–3. PMID 19043827. 
  99. ↑ Lardizabal, DV. (February 2009). "Intracranial hypertension and levofloxacin: a case report.". Headache 49 (2): 300–1. doi:10.1111/j.1526-4610.2008.01212.x. PMID 18647180. 
  100. ↑ Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG (2003). "Levofloxacin-induced autoimmune hemolytic anemia". Ann Pharmacother 37 (7-8): 1010–3. doi:10.1345/aph.1C525. PMID 12841809. 
  101. ↑ Iannini, PB. (June 2007). "The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.". Curr Med Res Opin 23 (6): 1403–13. doi:10.1185/030079907X188099. PMID 17559736. 
  102. ↑ Owens, RC.; Ambrose, PG. (July 2005). "Antimicrobial safety: focus on fluoroquinolones.". Clin Infect Dis 41 Suppl 2: S144–57. doi:10.1086/428055. PMID 15942881. 
  103. ↑ Saint, F.; Gueguen, G.; Biserte, J.; Fontaine, C.; Mazeman, E. (September 2000). "[Rupture of the patellar ligament one month after treatment with fluoroquinolone]". Rev Chir Orthop Reparatrice Appar Mot 86 (5): 495–7. PMID 10970974. 
  104. ↑ Gangopadhyay, N.; Daniell, M.; Weih, L.; Taylor, HR. (April 2000). "Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers." (PDF). Br J Ophthalmol 84 (4): 378–84. doi:10.1136/bjo.84.4.378. PMID 10729294. PMC 1723447. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1723447&blobtype=pdf. 
  105. ↑ Walter, K.; Tyler, ME. (August 2006). "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.". Cornea 25 (7): 855–7. doi:10.1097/01.ico.0000224642.43601.14. PMID 17068466. 
  106. ↑ "Public Citizen Warns of Cipro Dangers". USA: Consumer affairs. 30 August 2006. http://www.consumeraffairs.com/news04/2006/08/pubcit_cipro.html. Retrieved 7 September 2009. 
  107. ↑ "FDA orders 'black box' label on some antibiotics". CNN. 2008-07-08. http://www.cnn.com/2008/HEALTH/07/08/antibiotics.risk/index.html. Retrieved 2008-07-08. 
  108. ↑ Hirano T, Yasuda S, Osaka Y (March 2008). "The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo". International Journal of Pharmaceutics 351 (1-2): 113–8. doi:10.1016/j.ijpharm.2007.09.022. PMID 17977676. 
  109. ↑ Friedrich, LV.; Dougherty, R. (December 2004). "Fatal hypoglycemia associated with levofloxacin.". Pharmacotherapy 24 (12): 1807–12. doi:10.1592/phco.24.17.1807.52348. PMID 15585448. http://www.medscape.com/viewarticle/496197. 
  110. ↑ Melissa Hunt (January 2007). "Levofloxacin: dysglycemia and liver disorders" (PDF). Canadian adverse reaction newsletter (Canada: Health Canada Newsletter) 17 (1). http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/carn-bcei_v17n1-eng.pdf. 
  111. ↑ "Showing drug card for Rimantadine (DB00478)". Canada. 23 June 2009. http://www.drugbank.ca/drugs/DB00478. 
  112. ↑ Drlica K, Zhao X (1 September 1997). "DNA gyrase, topoisomerase IV, and the 4-quinolones". Microbiol Mol Biol Rev. 61 (3): 377–92. PMID 9293187. PMC 232616. http://mmbr.asm.org/cgi/pmidlookup?view=long&pmid=9293187. 
  113. ↑ Hussy P, Maass G, Tümmler B, Grosse F, Schomburg U (June 1986). "Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts". Antimicrob. Agents Chemother. 29 (6): 1073–8. PMID 3015015. PMC 180502. http://aac.asm.org/cgi/reprint/29/6/1073.pdf. 
  114. ↑ "Mutagenicity of norfloxacin and AM-833 in bacteria and mammalian cells". Rev. Infect. 1 (jstor.org) 10: S148–S149. 1988. http://www.jstor.org/pss/4454399. 
  115. ↑ Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF (May 1987). "Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth". Antimicrobial Agents and Chemotherapy 31 (5): 774–9. PMID 3606077. 
  116. ↑ Gootz TD, Barrett JF, Sutcliffe JA (January 1990). "Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems". Antimicrobial Agents and Chemotherapy 34 (1): 8–12. PMID 2158274. 
  117. ↑ Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC (February 1993). "4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells". Journal of Cellular Biochemistry 51 (2): 165–74. doi:10.1002/jcb.240510208. PMID 8440750. 
  118. ↑ Elsea SH, Osheroff N, Nitiss JL (5 July 1992). "Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast" (PDF). The Journal of Biological Chemistry 267 (19): 13150–3. PMID 1320012. http://www.jbc.org/cgi/pmidlookup?view=long&pmid=1320012. Retrieved 2009-06-03. 
  119. ↑ Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA (December 1992). "Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity". Journal of Medicinal Chemistry 35 (25): 4745–50. doi:10.1021/jm00103a013. PMID 1469702. 
  120. ↑ Enzmann H, Wiemann C, Ahr HJ, Schlüter G (April 1999). "Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver". Mutat. Res. 425 (2): 213–24. PMID 10216214. 
  121. ↑ Kashida Y, Sasaki YF, Ohsawa K (October 2002). "Mechanistic study on flumequine hepatocarcinogenicity focusing on DNA damage in mice". Toxicological Sciences : an Official Journal of the Society of Toxicology 69 (2): 317–21. doi:10.1093/toxsci/69.2.317. PMID 12377980. http://toxsci.oxfordjournals.org/cgi/content/full/69/2/317. Retrieved 2009-06-30. 
  122. ↑ Thomas A, Tocher J, Edwards DI (May 1990). "Electrochemical characteristics of five quinolone drugs and their effect on DNA damage and repair in Escherichia coli". The Journal of Antimicrobial Chemotherapy 25 (5): 733–44. doi:10.1093/jac/25.5.733. PMID 2165050. http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=2165050. Retrieved 2009-06-30. 
  123. ↑ "Fluoroquinolones and Quinolones". The American Academy of Optometry (British Chapter). http://www.academy.org.uk/pharmacy/fluoroq.htm. Retrieved 29 January 2009. 
  124. ↑ Yaseen A. Al-Soud; Najim A. Al-Masoudi (2003). "A new class of dihaloquinolones bearing N'-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and a-amino ester precursors: synthesis and antimicrobial activity". J. Braz. Chem. Soc 14 (5). doi:10.1590/S0103-50532003000500014. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532003000500014&lng=es&nrm=iso&tlng=es. "Nevertheless, some quinolones cause injury to the chromosome of eukaryotic cells.21,22 These findings prompted us to optimize the substituent at C-3, by...". 
  125. ↑ Yaseen A. Al-Soud a and Najim A. Al-Masoudi (2003). "A New Class of Dihaloquinolones Bearing N’-Aldehydoglycosylhydrazides, Mercapto-1,2,4-triazole, Oxadiazoline and α-Amino Ester Precursors: Synthesis and Antimicrobial Activity". J. Braz. Chem. Soc 14 (5): 790–796. http://jbcs.sbq.org.br/jbcs/2003/v14_n5/13-048-02.pdf. "Although the current quinolones are not considered to be potent inhibitors of eucaryotic topoisomerases, some effects on these and other enzymes involved with DNA replication have been observed". 
  126. ↑ Sissi C, Palumbo M (November 2003). "The quinolone family: from antibacterial to anticancer agents". Current Medicinal Chemistry. Anti-cancer Agents 3 (6): 439–50. doi:10.2174/1568011033482279. PMID 14529452. "The present review focuses on the structural modifications responsible for the transformation of an antibacterial into an anticancer agent. Indeed, a distinctive feature of drugs based on the quinolone structure is their remarkable ability to target different type II topoisomerase enzymes. In particular, some congeners of this drug family display high activity not only against bacterial topoisomerases, but also against eukaryotic topoisomerases and are toxic to cultured mammalian cells and in vivo tumor models". 
  127. ↑ Brouwers JR (1992). "Drug interactions with quinolone antibacterials". Drug Saf 7 (4): 268–81. doi:10.2165/00002018-199207040-00003. PMID 1524699. 
  128. ↑ Hilliard JJ, Krause HM, Bernstein JI (1995). "A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase". Adv Exp Med Biol. 390: 59–69. PMID 8718602. 
  129. ↑ Harder S, Fuhr U, Staib AH, Wolff T (November 1989). "Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations". Am. J. Med. 87 (5A): 89S–91S. doi:10.1016/0002-9343(89)90031-4. PMID 2589393. 
  130. ↑ Cooper JG, Harboe K, Frost SK, Skadberg Ø (April 2005). "Ciprofloxacin interacts with thyroid replacement therapy". BMJ 330 (7498): 1002. doi:10.1136/bmj.330.7498.1002. PMID 15860826. PMC 557149. http://www.bmj.com/cgi/content/full/330/7498/1002. 
  131. ↑ Domagala JM (April 1994). "Structure-activity and structure-side-effect relationships for the quinolone antibacterials". J. Antimicrob. Chemother. 33 (4): 685–706. doi:10.1093/jac/33.4.685. PMID 8056688. http://jac.oxfordjournals.org/cgi/reprint/33/4/685. 
  132. ↑ Janknegt R (November 1990). "Drug interactions with quinolones". J. Antimicrob. Chemother. 26 Suppl D: 7–29. PMID 2286594. 
  133. ↑ van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH (2003). "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids". Arch. Intern. Med. 163 (15): 1801–7. doi:10.1001/archinte.163.15.1801. PMID 12912715. http://archinte.ama-assn.org/cgi/content/full/163/15/1801. 
  134. ↑ JOHNSON & JOHNSON (28 March 2004). "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". USA: shareholder.com. pp. 28–29. http://apps.shareholder.com/sec/viewerContent.aspx?companyid=JNJ&docid=2940855. 
  135. ↑ "NDA 20-634/S-054, NDA 20-635/S-059, NDA 21-721/S-022" (PDF). USA: FDA. 12 March 2009. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/020634s054,020635s059,021721s022ltr.pdf. 
  136. ↑ Ozlem Belen (27 March 2009). "NDA 20-634/S-053, NDA 20-635/S-058, NDA 21-721/S-021" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/020634s053,020635s058,021721s021lt.pdf. 
  137. ↑ Ortho-McNeil-Janssen Pharmaceuticals, Inc. (October 2008). "FDA-Approved Medication Guide" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020634s053,020635s058,%20021721s021lbl.pdf. 
  138. ↑ Renata Albrecht (3 October 2008). "NDA 19-735/S-059" (PDF). USA: FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/019735s059ltr.pdf. 
  139. ↑ Bailey RR, Natale R, Linton AL (October 1972). "Nalidixic acid arthralgia". Can Med Assoc J 107 (7): 604 passim. PMID 4541768. 
  140. ↑ Bailey RR, Kirk JA, Peddie BA (July 1983). "Norfloxacin-induced rheumatic disease". N Z Med J 96 (736): 590. PMID 6223241. 
  141. ↑ Szarfman A, Chen M, Blum MD (January 1995). "More on fluoroquinolone antibiotics and tendon rupture" (letter). N Engl J Med 332 (3): 193. doi:10.1056/NEJM199501193320319. PMID 7800023. 
  142. ↑ 142.0 142.1 "Petition to Require a Warning on All Fluoroquinolone Antibiotics (HRG Publication #1399)". Public Citizen. August 1, 1996. http://www.citizen.org/publications/release.cfm?ID=6595.  Retrieved on December 27, 2008.
  143. ↑ "Reports of adverse events with fluoroquinolones". FDA Medical Bulletin 26 (3). October 1996. http://www.fda.gov/medbull/oct96/adverse.html.  Retrieved on December 27, 2008. alternate link: http://www.fqresearch.org/text_documents/FDA_Medical_Bulletin_1996.doc
  144. ↑ 144.0 144.1 Office of the Illinois Attorney General (August 29, 2006). "Madigan, Public Citizen, petition FDA for "black box" warning regarding potential adverse effects of certain popular antibiotics". Press release. http://www.illinoisattorneygeneral.gov/pressroom/2006_08/20060829.html. Retrieved 2008-12-27.  Full text of the 2005 petition and FDA response available from the Fluoroquinolone Toxicity Research Foundation, a U.S. consumer advocacy group.
  145. ↑ 145.0 145.1 "Public Citizen Petitions the FDA to Include a Black Box Warning on Fluoroquinolone Antibiotics (HRG Publication #1781)". Public Citizen. August 29, 2006. http://www.citizen.org/publications/release.cfm?ID=7453. Retrieved 2008-12-27. 
  146. ↑ "Public Citizen v. Food and Drug Administration (FDA) (Fluoroquinolone)". Public Citizen. January 3, 2008. http://www.citizen.org/litigation/forms/cases/CaseDetails.cfm?cID=444. Retrieved 2008-12-27. 
  147. ↑ Ravn, Karen (August 18, 2008). "Behind the FDA’s ‘black box’ warnings". Los Angeles Times. http://articles.latimes.com/2008/aug/18/health/he-closer18. Retrieved 2008-12-27. 
  148. ↑ U.S. Food and Drug Administration (2008-07-08). "FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs". Press release. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01858.html. Retrieved 2008-10-11. 
  149. ↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116919.htm
  150. ↑ MacCarthy, Paul (October 22, 2008). "Important Change in the Avelox (moxifloxacin hydrochloride) and Cipro (ciprofloxacin) Complete Prescribing Information – Addition of Boxed Warning and Medication Guide Regarding Tendinitis and Tendon Rupture". Bayer HealthCare Pharmaceuticals. http://www.cipro.com/html/pdf/dhpl.pdf. Retrieved 2008-12-27. 
  151. ↑ M Jacobs, Worldwide Overview of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005.
  152. ↑ Robicsek A, Jacoby GA, Hooper DC (October 2006). "The worldwide emergence of plasmid-mediated quinolone resistance". The Lancet Infectious Diseases 6 (10): 629–40. doi:10.1016/S1473-3099(06)70599-0. PMID 17008172. 
  153. ↑ Jim Hoover, for Bayer Corporation, Alaska Pharmacy and Therapeutics Committee March 19, 2004
  154. ↑ Froom J, Culpepper L, Jacobs M (July 1997). "Antimicrobials for acute otitis media? A review from the International Primary Care Network". BMJ (Clinical Research Ed.) 315 (7100): 98–102. PMID 9240050. 
  155. ↑ Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS (March 2005). "Fluoroquinolone prescribing in the United States: 1995 to 2002". The American Journal of Medicine 118 (3): 259–68. doi:10.1016/j.amjmed.2004.09.015. PMID 15745724. 
  156. ↑ K08 HS14563 and HS11313
  157. ↑ Public Citizen; Michael T. Kickpatrick (3 January 2008). "In The United States District Court For The District Of Columbia" (PDF). USA: Carey & Danis, LLC. Archived from the original on 2008. http://www.fqresearch.org/fda_suit.htm. 
  158. ↑ Lisa Madigan (18 May 2005). "Office Of The Attorney General State Of Illinois, CITIZEN PETITION" (PDF). USA: FDA. Archived from the original on 2005. http://www.fqresearch.org/pdf_files/fda_response.pdf. 
  159. ↑ Jane A. Axelrad (16 November 2005). "Re: Docket No. 2005P-0205" (PDF). USA: FDA. http://www.fqresearch.org/pdf_files/illinois.pdf. 
  160. ↑ Michael A. Friedman, M.D. (9 June 1998). "Petition to the Food and Drug Administration to immediately stop the distribution of dangerous, misleading prescription drug information to the public. (HRG Publication #1442)". USA: Public Citizen. Archived from the original on 2007. http://fqresearch.org/HRG_Publication_1442.htm. 
  161. ↑ Public Citizen. "Patently Offensive: Congress Set to Extend Monopoly Patents for Cipro and Other Drugs". USA: Citizen.org. http://www.citizen.org/print_article.cfm?ID=6435. 
  162. ↑ Noel GJ, Bradley JS, Kauffman RE (October 2007). "Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders". Pediatr. Infect. Dis. J. 26 (10): 879–91. doi:10.1097/INF.0b013e3180cbd382. PMID 17901792. 
  163. ↑ "SYNOPSIS" (PDF). USA: Veritas Medicine. 30 June 2004. http://download.veritasmedicine.com/PDF/CR002389_CSR.pdf. Retrieved 13 August 2009. 
  164. ↑ Johnson&Johnson accused of paying kickbacks to pharmacy chain Omnicare By Susan Todd/The Star-Ledger January 15, 2010, 8:12PM http://www.nj.com/business/index.ssf/2010/01/johnsonjohnson_accused_of_payi.html
  165. ↑ Johnson & Johnson Accused of Drug Kickbacks By NATASHA SINGER Published: January 15, 2010 http://www.nytimes.com/2010/01/16/business/16drug.html
  166. ↑ http://newsfeedresearcher.com/data/articles_b4/johnson-omnicare-drug.html
  167. ↑ Judge John R. Tunheim. "Levaquin MDL". USA: US Courts. http://www.mnd.uscourts.gov/MDL-Levaquin/index.shtml. Retrieved 7 September 2009. 
  168. ↑ Charles Toutant (6 July 2009). "Litigation Over Johnson & Johnson Antibiotic Levaquin Designated N.J. Mass Tort". New Jersey Law Journal. http://www.law.com/jsp/article.jsp?id=1202431984309. 
  169. ↑ Carey and Danis LLC (3 September 2009). "Carey and Danis LLC Announces Four Lawsuits against the Makers of Levaquin". Reuters. http://www.reuters.com/article/pressRelease/idUS199242+03-Sep-2009+BW20090903. 
  170. ↑ The Southeast Texas Record. Apr. 17, 2010 S.E. Texas' Legal Journal Class action alleges antibiotic causes tendon damage 4/15/2010 8:21 AM By Michelle Massey, East Texas Bureau http://www.setexasrecord.com/news/226050-class-action-alleges-antibiotic-causes-tendon-damage
  171. ↑ The United States District Court District Of Minnesota (12 May 2009). "DEFENDANT JOHNSON & JOHNSON'S ANSWER TO PLAINTIFF'S COMPLAINT" (PDF). USA. http://www.fqresearch.org/pdf_files/232-1.pdf. 
  172. ↑ "Anthrax Scare Leaves Trail of Cipro Victims - Class Actions filed in Two States". USA: Sheller Ludwig & Sheller. 17 October 2003. http://www.sheller.com/NewsDetails.asp?NewsID=72. Retrieved 9 September 2009. 
  173. ↑ "LEGAL BRIEF of Postal Employees Cases (EEOC, MSPB, District Courts)". USA: Postal Reporter. http://www.lunewsviews.com/legal_briefs_archives.htm#cipro. Retrieved 9 September 2009. 
  174. ↑ Charles P. Goodell, Jr. "Profile". USA: Goodell, DeVries, Leech & Dann, LLP. http://www.gdldlaw.com/content/bio_goodell.htm. Retrieved 9 September 2009. 

External links


Antibacterials: nucleic acid inhibitors (J01E, J01M)
Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis)
DR inhibitor
2,4-Diaminopyrimidine (Trimethoprim#, Brodimoprim, Tetroxoprim, Iclaprim†)
Sulfonamides
(DS inhibitor)
Sulfaisodimidine · Sulfamethizole · Sulfadimidine · Sulfapyridine · Sulfafurazole · Sulfanilamide (Prontosil) · Sulfathiazole · Sulfathiourea
Sulfamethoxazole · Sulfadiazine# · Sulfamoxole
Sulfadimethoxine · Sulfalene · Sulfametomidine · Sulfametoxydiazine · Sulfamethoxypyridazine · Sulfaperin · Sulfamerazine · Sulfaphenazole · Sulfamazone
Other/ungrouped
sulfanilamide (Sulfacetamide, Sulfametrole)
Combinations
Sulfamethoxazole and trimethoprim#
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication)
Cinoxacin‡ · Flumequine · Nalidixic acid · Oxolinic acid · Pipemidic acid · Piromidic acid · Rosoxacin
Ciprofloxacin#  · Enoxacin‡ · Fleroxacin‡ · Lomefloxacin · Nadifloxacin · Ofloxacin · Norfloxacin · Pefloxacin · Rufloxacin
Balofloxacin · Grepafloxacin‡ · Levofloxacin · Pazufloxacin · Sparfloxacin‡ · Temafloxacin‡ · Tosufloxacin
Besifloxacin · Clinafloxacin† · Garenoxacin · Gemifloxacin · Moxifloxacin · Gatifloxacin‡ · Sitafloxacin · Trovafloxacin‡/Alatrofloxacin‡ · Prulifloxacin
Danofloxacin · Difloxacin · Enrofloxacin · Ibafloxacin · Marbofloxacin · Orbifloxacin · Pradofloxacin · Sarafloxacin
Related (DG)
Aminocoumarins: Novobiocin
Anaerobic DNA
inhibitors
Nitro- imidazole derivatives
Metronidazole#  · Tinidazole · Ornidazole
Nitrofuran derivatives
Nitrofurantoin#  · Furazolidone‡  · Nifurtoinol
RNA synthesis
Rifamycins/
RNA polymerase
Rifampicin · Rifabutin · Rifapentine · Rifaximin
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

: BAC

bact (clas)

gr+f/gr+a(t)/gr-p(c)/gr-o

drug(J1p, w, n, m, vacc)